Page 22 - Journal of Structural Heart Disease Volume 5, Issue 6

Original Scientific Article
246
Base on our experience, successful closure was achieved in 92.8% of the cases, without major compli- cations and minimal or no residual shunt. The failed procedure was due to the appearance of transient complete AV block during a reposition maneuver of the device that caused to refer the closure to surgery.
Regarding the group of patients under 5 kg who had severe cardiac diseases, (TCGA with mid-ven- tricular VSD, critical aortic stenosis with severe aortic coarctation, Total anomalous pulmonary venous con- nection (TAPVC), the decision was taken to repair the most severe emergent pathology that was putting the patient’s life at risk through VSD with the MFO, due to the versatility of the device.
One of the main strengths of this novel device is the presence of a double hub that allows an antero- grade or retrograde approach, as well as the low-pro- file delivery system that allows the closing of large VSDs in low-weigh patients under 5 Kg.
One of the disadvantages of the device in peri- membranous VSDs with prolapse of the aortic sig- moid is the symmetrical diameter of the discs that can compromise the function of the aortic valve. As well the length of the right hub (7mm) can injure the tricuspid valve during the device implantation.
This is the first publication of the novel device“MFO” for endovascular VSD closure that is in full develop- ment with satisfactory short and mid-term results.
Conclusion
The device increase the possibility of closure of dif- ferent types of VSD since it allows choosing the ante- grade or retrograde approach as well as the closing of a great variety of sizes of VSD and the occlusion of large defects in low-weight patients.
The learning curve of the device, will let us know more details about MFO including the success rate of VSD closure.
Acknowledgments
The author would like to thank Yafeng Luo, region- al business manager of Lifetech; Shuanglan He, busi- ness manager of Lifetech; and Javier Varde, Lifetech business manager in Argentina, for the collaboration and support to make MFO happen in Argentina.
Conflict of Interest
The authors have no conflict of interest relevant to this publication.
Comment on this Article or Ask a Question
References
1. Mc Daniel NL, Gutgesell HP. Ventricular Septal Defects. Moss and Adams’ Heart Dis- ease in Infants, Children, and Adolescents: Including the Fetus and Young Adults, 7th Edition. Chapter 32.
2. Hoffman JI, Kaplan S. The incidence of con- genital heart disease. J Am Coll Cardiol. 2002;39:1890-1900. DOI: 10.1016/S0735- 1097(02)01886-7
3. Mavroudis C, Backer CL, Jacobs JP. Ventric- ular septal defect. Pediatric Cardiothoracic Surgery 3rd Mosby, p298-320.
4. Wollenek G, Wyse R, Sullivan I, Elliot M, de Leval M, Stark J. Closure of muscular ventricular septal defects through a left ventriculotomy. Eur J Cardiothorac Surg. 1996;10:595-598. DOI: 10.1016/S1010- 7940(96)80371-X
5. Bol-Raap G, Weerheim J, Kappetein AP, Witsenburg M, Bogers AJ. Follow-up after surgical closure of congenital ventricular septal defects. Eur J Cardiothorac Surg. 2003;24:511-515. DOI: 10.1016/S1010-
7940(03)00430-5
6. Vázquez F, Mirabal R, González O, González A, Rodríguez O, et al. Resultados del trat- amiento quirúrgico de la comunicación interventricular en pacientes pediátricos. Anales de Cirugía Cardíaca y Vascular. 12:28-33.
7. Carminati M, Butera G, Chessa M, De Giovanni J, Fisher G, Gewillig M, et. al. Transcatheter closure of congenital ven- tricular septal defects: results of the Eu- ropean Registry. European Heart Jour- nal. 2007;28:2361-2368. DOI: 10.1093/ eurheartj/ehm314
8. Zhu XY, Liu YH, Hou CJ, Han XM, Sheng XT, Zhang DZ, et al. Risk factors for early arrhythmias post transcatheter closure of perimembranous ventricular septal de- fects. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:633-636. PMID: 17961429
9. Nogi S, Haneda N, Tomita H and Yasuda K. Transcatheter Coil Occlusion of Perimem- branous Ventricular Septal Defects. Cardio-
vascular Interventions. 2008;72:683-690.
DOI: 10.1002/ccd.21703
10. Michel-Behnke I, Le TP, Waldecker B,
Akintuerk H, Valeske K, Schranz D. Per- cutaneous closure of congenital and acquired ventricular septal defects. Con- siderations on selection of the occlusion device. J Interv Cardiol. 2005;18:89-99. DOI: 10.1111/j.1540-8183.2005.04051.x
11. Hijazi ZM, Hakim F, Al-Fadley F, Abdelhamid J, Cao Q-L. Transcatheter Closure of Single Muscular Ventricular Septal Defects Using the Amplatzer Muscular VSD Occluder: Ini- tial Results and Technical Considerations. Catheterization and Cardiovascular Inter- ventions. 2000;49:167-172. DOI: 10.1002/ (SICI)1522-726X(200002)49:2<167::AID- CCD11>3.0.CO;2-S
12. Jameel AA, Arfi AM, Arif H, Amjad K, Omar GM. Retrograde Approach for Device Clo- sure of Muscular Ventricular Septal De- fects in Children and Adolescents, Using the Amplatzer Muscular Ventricular Sep-
Journal of Structural Heart Disease, December 2019
Volume 5, Issue 6:237-247